Nicolas Leupin
Chief Tech/Sci/R&D Officer chez NOVOCURE LIMITED
Fortune : 918 078 $ au 31/03/2024
Profil
Nicolas Leupin is currently the Chief Medical Officer at NovoCure Ltd.
He previously held the same position at Molecular Partners AG from 2019 to 2023 and at argenx SE from 2016 to 2019.
He was also a member of the Swiss Group for Clinical Research.
Leupin holds an MBA from Jones International University and a doctorate from the University of Bern.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NOVOCURE LTD.
0,05% | 27/02/2024 | 51 124 ( 0,05% ) | 799 068 $ | 31/03/2024 |
MOLECULAR PARTNERS AG
0,08% | 31/12/2023 | 29 168 ( 0,08% ) | 119 010 $ | 31/03/2024 |
Postes actifs de Nicolas Leupin
| Sociétés | Poste | Début |
|---|---|---|
| NOVOCURE LIMITED | Chief Tech/Sci/R&D Officer | 04/01/2024 |
Anciens postes connus de Nicolas Leupin
| Sociétés | Poste | Fin |
|---|---|---|
| MOLECULAR PARTNERS AG | Chief Tech/Sci/R&D Officer | 24/08/2023 |
| ARGENX SE | Chief Tech/Sci/R&D Officer | 01/07/2019 |
| Swiss Group for Clinical Research | Corporate Officer/Principal | - |
Formation de Nicolas Leupin
| Jones International University | Masters Business Admin |
| University of Bern | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| MOLECULAR PARTNERS AG | Health Technology |
| NOVOCURE LIMITED | Health Technology |
| ARGENX SE | Health Technology |
| Entreprise privées | 1 |
|---|---|
| Swiss Group for Clinical Research |
